Clinical Trials Directory
In this study, people are placed into one of two groups based on certain features found in their genes. The first group, called Cohort 1, includes people who have low‑risk genetic signs. To be in this group, a person must have a mutated IGHV gene, must not have a 17p deletion, and must not have a TP53 mutation. All three conditions must be true. People in this group will first take a medicine called acalabrutinib for two cycles. After that, they will take a combination of acalabrutinib and venetoclax, called AV, for twelve more cycles. The second group, called Cohort 2, includes people who have any high‑risk genetic signs. This may include having an unmutated IGHV gene, a 17p deletion, a TP53 mutation, or a mix of these.
We are doing this study to find out if an experimental drug called ataciguant (the study drug) is an effective option to slow the rate of calcium deposits in the aortic valve for people who have aortic stenosis.
If you join this study, you will have a procedure where the study medicine is placed into the back of your eye. After this, you will return for follow up visits for up to five years so doctors can check how your eyes are doing. There will be about seventeen visits in total. At these visits, doctors will test your vision and examine your eyes to watch for changes and make sure the treatment is safe.
We are doing this study to find out if an experimental drug called efzofitimod (the study drug) is a safe and effective option for people with SSc-ILD. We want to know how well the study drug works against the skin and lung effects caused by SSc-ILD.
This study is testing a new medicine called MYK-224 to help people with a heart problem called HFpEF. That means their heart pumps well but does not relax properly. People in the study also have signs that their heart is not working normally. The study has four groups, called cohorts. Duke is only helping with Cohort 4, which will include about 160 people. These people will be split into four smaller groups. Three groups will get different amounts of the real medicine, and one group will get a fake medicine called a placebo. The treatment will last 20 weeks. A special team of doctors will check to make sure the medicine is safe and decide how much each group should get. To join the study, people must meet certain health rules.
We are doing this study to find out if a program called AYA STEPS has a positive benefit for young people who are treated for cancer. We want to know how well this program can help cancer survivors younger than 40 manage any physical or emotional symptoms they have after treatment, and we also want to see if the program can help them be more engaged with follow-up care.
This study includes a screening visit, a treatment period lasting 8 to 12 weeks, and a follow-up. During the screening, you will have a medical exam, and information about your health and background will be collected from your hospital records. If you qualify and choose to join, you will take Vitamin B6 once a day for 8 to 12 weeks. You and a caregiver will receive study questionnaires electronically. These will be sent within 7 days after you join the study, before you start taking Vitamin B6, and again after your follow-up visit. You will have up to 14 days to complete each set of questionnaires. There is no special visit at the end of treatment. The study ends once you finish the final set of questionnaires after taking Vitamin B6.
We are doing this study to test different drugs to see if they are safe and helpful for adults who are admitted in the hospital with acute respiratory distress syndrome (ARDS) compared to placebo (a substance that looks like a drug but does not contain an active drug).